We retrospectively investigated whether administration of 1 mg of
intramuscular (IM) glucagon to decrease bowel peristalsis prior to prostate MRI
decreases motion artifact. Two blinded, independent readers reviewed MRI
prostate studies of 25 and 26 patients who did and did not receive glucagon,
respectively, for motion-related blurring of the prostate, bowel, and lymph
nodes on a five-point Likert scale. No significant difference was observed in
all categories. Although European Society of Uroradiology (ESUR) and American
College of Radiology guidelines recommend using antiperistaltic agents for
prostate MRI, our results suggest that IM glucagon may not be necessary.
